Rufinamide improves functional and behavioral deficits via blockade of tetrodotoxin-resistant sodium channels in diabetic neuropathy

Current Neurovascular Research

Volumn 12, Issue 3, 2015, Pages 262-268

  Kharatmal, Shivsharan B ^a   Singh, Jitendra N ^a   Sharma, Shyam S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Diabetic neuropathy; Dorsal root ganglion; Rufinamide; Voltage gated sodium channel; Whole cell patch clamp

Indexed keywords

RUFINAMIDE; SODIUM CHANNEL; TETRODOTOXIN; GLUCOSE BLOOD LEVEL; SODIUM CHANNEL BLOCKING AGENT; TRIAZOLE DERIVATIVE;

ADULT; ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG DOSE COMPARISON; FUNCTIONAL ASSESSMENT; HYPERALGESIA; HYPERPOLARIZATION; MALE; MOTOR NERVE CONDUCTION; NOCICEPTION; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; SODIUM CURRENT; SPINAL GANGLION; STEADY STATE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VOLTAGE CLAMP TECHNIQUE; ANIMAL; BIOPHYSICS; BLOOD; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ELECTROSTIMULATION; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; MENTAL DISORDERS; NERVE CELL; NERVE CONDUCTION; PATCH CLAMP TECHNIQUE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BIOPHYSICAL PHENOMENA; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; GANGLIA, SPINAL; MENTAL DISORDERS; NEURAL CONDUCTION; NEURONS; PATCH-CLAMP TECHNIQUES; RATS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TETRODOTOXIN; TRIAZOLES;

EID: 84937126687     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202612666150603130402     Document Type: Article

References (38)

1. Arroyo S. Rufinamide. Neurotherapeutics 2007; 4(1): 155-62.
2. Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012; 64(10): 887-95.
3. Besag FM. Rufinamide for the treatment of Lennox-Gastaut syndrome. Expert Opin Pharmacother 2011; 12(5): 801-6.
4. Kim SH, Eun SH, Kang HC, et al. Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome. Seizure 2012; 21(4): 288-91.
5. Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S. Adjunctive rufinamide in Lennox-Gastaut syndrome: a longterm, open-label extension study. Acta Neurol Scand 2010; 122(3): 202-8.
6. Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW. Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother 2007; 8(12): 1931-40.
7. Wisniewski CS. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome. Ann Pharmacother 2010; 44(4): 658-67.
8. Alsaad AM, Koren G. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. Br J Clin Pharmacol 2014; 78(6): 1264-71.
9. Deeks ED, Scott LJ. Rufinamide. CNS Drugs 2006; 20(9): 751-60; discussion 61.
10. Suter MR, Kirschmann G, Laedermann CJ, Abriel H, Decosterd I. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology 2013; 118(1): 160-72.
11. Horowitz SH. Diabetic neuropathy. Clin Orthop Relat Res 1993; (296): 78-85.
12. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29(7): 1518-22.
13. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47(2): 123-8.
14. Lauria G, Ziegler D, Malik R, Merkies IS, Waxman SG, Faber CG. The role of sodium channels in painful diabetic and idiopathic neuropathy. Curr Diab Rep 2014; 14(10): 538.
15. Dib-Hajj SD, Black JA, Waxman SG. Voltage-gated sodium channels: therapeutic targets for pain. Pain Med 2009; 10(7): 1260-9.
16. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain 2007; 131(3): 243-57.
17. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005; 57(4): 397-409.
18. Waxman SG. The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Pain 1999; Suppl 6: S133-40.
19. Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proc Natl Acad Sci USA 1999; 96(14): 7635-9.
20. Bierhaus A, Fleming T, Stoyanov S, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012; 18(6): 926-33.
21. Hong S, Morrow TJ, Paulson PE, Isom LL, Wiley JW. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem 2004; 279(28): 29341-50.
22. Meerupally R, Singh JN, Sharma SS. Diabetic-induced increased sodium channel activity attenuated by tetracaine in sensory neurons in vitro. Biochem Biophys Res Commun 2014; 453(3): 296-301.
23. Negi G, Kumar A, Sharma SS. Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010; 391(1): 102-6.
24. Negi G, Kumar A, Sharma SS. Nrf2 and NF-kappaB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes. Curr Neurovasc Res 2011; 8(4): 294-304.
25. Negi G, Sharma SS. Inhibition of IkappaB Kinase (IKK) Protects Against Peripheral Nerve Dysfunction of Experimental Diabetes. Mol Neurobiol 2015; 51(2): 591-8.
26. Singh JN, Jain G, Ramarao P, Sharma SS. Inhibition of sodium current by carbamazepine in dorsal root ganglion neurons in vitro. Indian J Physiol Pharmacol 2009; 53(2): 147-54.
27. Singh JN, Jain G, Sharma SS. In vitro hyperglycemia enhances sodium currents in dorsal root ganglion neurons: an effect attenuated by carbamazepine. Neuroscience 2013; 232: 64-73.
28. Priest BT, Kaczorowski GJ. Blocking sodium channels to treat neuropathic pain. Expert Opin Ther Targets 2007; 11(3): 291-306.
29. Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol 2006; 539(1-2): 64-70.
30. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007; 13(1): 21-42.
31. Stohr T, Krause E, Selve N. Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain 2006; 10(3): 241-9.
32. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008; 73(1): 157-69.
33. Fox A, Gentry C, Patel S, Kesingland A, Bevan S. Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and Guinea-pig. Pain 2003; 105(1-2): 355-62.
34. Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther 2002; 302(3): 1168-75.
35. Nakamura-Craig M, Follenfant RL. Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes. Pain 1995; 63(1): 33-7.
36. Stummann TC, Salvati P, Fariello RG, Faravelli L. The antinociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neurons. Eur J Pharmacol 2005; 510(3): 197-208.
37. Veneroni O, Maj R, Calabresi M, Faravelli L, Fariello RG, Salvati P. Anti-allodynic effect of NW-1029, a novel Na(+) channel blocker, in experimental animal models of inflammatory and neuropathic pain. Pain 2003; 102(1-2): 17-25.
38. Mert T, Gunes Y. Antinociceptive activities of lidocaine and the nav1.8 blocker a803467 in diabetic rats. J Am Assoc Lab Anim Sci 2012; 51(5): 579-85.